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Introduction
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most
lethal cancers with a 5-year survival of less than 11%, which leads to
432,242 yearly new deaths worldwide (1, 2). Recent pancreatic cancer
genome sequencing demonstrated an accumulation of genetic alterations in epigenetic regulating genes in addition to the common
oncogenes and tumor suppressor genes (e.g., KRAS, TP53, CDNK2A,
and SMAD4; refs. 3, 4). In particular, lysine (K)-speciﬁc demethylase
6A (KDM6A), also known as ubiquitously transcribed X chromosome
tetratricopeptide repeat protein, has emerged as an important epigenetic regulator in PDAC. KDM6A is located on the X chromosome, but
it escapes X inactivation in mice and humans (5). Functionally,
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recruited neutrophils. Furthermore, in a syngeneic orthotopic
mouse model, treatment with a CXCL1 neutralizing antibody
blocked the chemotactic and NET-promoting properties of
KDM6A-deﬁcient PDAC cells and suppressed tumor growth, conﬁrming CXCL1 as a key mediator of chemotaxis and PDAC growth
driven by KDM6A loss. These ﬁndings shed light on how KDM6A
regulates the tumor immune microenvironment and PDAC progression and suggests that the CXCL1–CXCR2 axis may be a
candidate target in PDAC with KDM6A loss.
Signiﬁcance: KDM6A loss in pancreatic cancer cells alters
the immune microenvironment by increasing CXCL1 secretion
and neutrophil recruitment, providing a rationale for targeting
the CXCL1–CXCR2 signaling axis in tumors with low KDM6A.
KDM6A catalyzes the demethylation of trimethylated histone H3
lysine 27 (H3K27me3). Together with MLL methyltransferase and
CBP/P300 in the COMplex of Proteins Associated with Set1-like
complex, KDM6A regulates the transcription and expression of
downstream genes, thereby regulating cell fate and cell functional
characteristics, which is particularly important for normal pancreatic
development (6, 7). The deletion of KDM6A promotes proliferation,
invasion, and metastasis of PDAC, and it is an independent prognostic
factor of PDAC (8, 9). Our previous study had shown that loss of
KDM6A induces an aggressive undifferentiated subtype of PDAC by
promoting epithelial–mesenchymal transition (EMT) via a p38dependent noncanonical activin A signaling using a genetically engineered PDAC mouse model (10). Meanwhile, we also discovered that
KDM6A deﬁciency promotes persistent acinar-to-ductal metaplasia
and inﬂammation in a well-established cerulein-induced chronic
pancreatitis mouse model, which may explain its role in accelerating
KRAS-induced pancreatic tumorigenesis (10). This ﬁnding implied
that loss of KDM6A might lead to an abnormal immune response to
tissue damages and interfere with normal tissue repair (11). Immune
cells are crucial elements in the pancreatic tumor microenvironment
(TME; ref. 12). However, how KDM6A deﬁciency affects the immune
microenvironment of PDAC remains unknown.
Recent studies showed that epigenetics impact the remodeling of
the immune microenvironment by regulating the expression of
cytokines or chemokines in tumor cells (13, 14). Moreover, emerging studies suggest that KDM6A deﬁciency may promote the
development of tumors by remodeling the tumor immune microenvironment. For example, in bladder cancer, the deﬁciency of
KDM6A in cancer cells promoted the polarization of macrophages
into M2 type by activating the cytokine and chemokine pathways
and led to the development of bladder cancer (13). In medulloblastoma, deletion of KDM6A signiﬁcantly reduced the recruitment
of CD8þ T lymphocytes (14).
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Lysine (K)-speciﬁc demethylase 6A (KDM6A) is a frequently
mutated tumor suppressor gene in pancreatic ductal adenocarcinoma (PDAC). However, the impact of KDM6A loss on the PDAC
tumor immune microenvironment is not known. This study used a
genetically engineered, pancreas-speciﬁc Kdm6a knockout (KO)
PDAC mouse model and human PDAC tissue samples to demonstrate that KDM6A loss correlates with increased tumor-associated
neutrophils and neutrophil extracellular traps (NET) formation,
which are known to contribute to PDAC progression. Genomewide bromouridine sequencing analysis to evaluate nascent RNA
synthesis showed that the expression of many chemotactic cytokines, especially CXC motif chemokine ligand 1 (CXCL1), was
upregulated in KDM6A KO PDAC cells. KDM6A-deﬁcient PDAC
cells secreted higher levels of CXCL1 protein, which in turn
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In this study, we used human PDAC samples, genetically engineered
mouse PDAC models, and in vitro PDAC cell lines to explore the role
of KDM6A deﬁciency in the tumor immune microenvironment and
ﬁnd potential therapeutic targets in PDACs with KDM6A loss.

Materials and Methods

Animal study
To generate the genetically engineered pancreas speciﬁc Kdm6a
knockout (KO) mouse model, we ﬁrst crossed Ptf1aCre mice (kindly
shared by Dr. Christopher Wright) with Kdm6aﬂ/ﬂ (female)
or Kdm6aﬂ/Y(male) mice (Jackson Laboratory, #024177) to get
Ptf1aCre Kdm6aﬂ/ﬂ (female homozygous Kdm6a KO) or Ptf1aCre
Kdm6aﬂ/Y (male hemizygous Kdm6a KO). Then we crossed LSLKrasG12D/wt;LSL-p53R172H/wt (kindly shared by Dr. Tyler Jacks)
with Ptf1aCre Kdm6aﬂ/ﬂ or Ptf1aCre Kdm6aﬂ/Y to generate ﬁve
different genotypes of mice (KPC- Kdm6aY/þ, KPC- Kdm6aY/ﬂ,
KPC- Kdm6aþ/þ, KPC- Kdm6aþ/ﬂ, and KPC- Kdm6aﬂ/ﬂ). All the
animal studies were performed under the reviewed and approved
animal protocol (#PRO00007450) by the Unit of Laboratory Animal
Medicine at the University of Michigan.
For orthotopic mouse models, 5104 KPC 7940 cells (a gift from Dr.
Gregory Beatty) in 40-mL Matrigel and cell culture media (1:1) were
injected into the pancreata of 6- to 8-week-old C57BL/6J mice. IgG or
anti—CXC motif chemokine ligand 1 (CXCL1) antibody (4 mg/kg,
MAB453–500, R&D Systems) was intraperitoneally injected twice a
week from the 8th day of tumor injection. Four weeks after the tumor
cell injection, mice were euthanized, and tumor tissues were collected
and ﬁxed in formalin.
Cell lines
PANC-1 cells (ATCC) and mouse KPC 7940 cells were cultured
in DMEM (Gibco) supplemented with 10% FBS (Gibco) and 1%
penicillin/streptomycin (Gibco). HPAF-II cells (ATCC) were cultured in Eagle Minimum Essential Medium with 10% FBS (Gibco)
and 1% penicillin/streptomycin (Gibco). HPDE cells (a gift from Dr.
Craig Logsdon) were cultured in Keratinocyte SFM with EGF,
bovine pituitary extract (Invitrogen), and 1% penicillin/streptomycin (Gibco). All cells were cultured at 37 C with 5% CO2. PLB-985
cells (kindly provided by Dr. Alan Smrcka) were cultured in
RPMI1640þGlutaMAX (Gibco) supplemented with 10% heatinactivated FBS and 1% penicillin/streptomycin (Gibco). For
PLB-985 cell differentiation, 0.5106 cells/mL was cultured in fully
supplemented RPMI media with 1.3% DMSO. The media was
changed every 2 days. After 5 days, differentiated PLB-985 cells
were ready for the chemotaxis assay.
Cell lines were authenticated by DNA ﬁngerprinting using the
AmpFISTR Ampliﬁcation or AmpFISTR Proﬁler PCR Ampliﬁcation
protocols (Life Technologies) and were negative for Mycoplasma.
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Bromouridine sequencing and gene set enrichment analysis
Bromouridine sequencing (Bru-seq) was performed as previously
described (14, 16). Brieﬂy, PANC-1 cells were incubated in bromouridine (Bru; 2 mmol/L, Sigma-Aldrich) contained media for 30 minutes
at 37 C. Cells were then lysed in TRIzol, and total RNA was isolated.
Bru-labeled RNA was immunocaptured using anti-BrdU antibodies
(BD Pharmingen, 555627). Then strand-speciﬁc cDNA libraries were
prepared using the Illumina TruSeq Kit (Illumina), followed by deep
sequencing using the Illumina sequencing platform as previously
described (14, 17, 18).
The difference in expression proﬁle was pre-ranked on the basis of
rLogFC value with a cutoff of 300 bp to eliminate the signal from noise
or background. The pre-ranked ﬁle was loaded into the gene set
enrichment analysis (GSEA) software tool (Broad Institute, Inc.,
Massachusetts Institute of Technology, and Regents of the University
of California) for analysis of the upregulated pathways that are
enriched in a positive or negative manner. The list of the top 10 gene
sets is represented by a bar graph based on their normalized enrichment score.
RNA extraction and quantitative real-time RT-PCR
Total RNAs were isolated using the RNeasy Mini Kit (QIAGEN)
according to the manufacturer’s directions. cDNA was prepared using
the SuperScript III First-Strand Synthesis Kit (Invitrogen). Quantitative RT-PCR of RNA was performed with SYBR Green reagents
(Applied Biosystems) in MicroAmp Optical 96-well reaction plates
(Applied Biosystems). Primer sequences are listed in Supplementary
Table S2.
Chromatin immunoprecipitation and real-time PCR
Chromatin immunoprecipitation (ChIP) was performed following
the manufacturer’s instructions (Cell Signaling Technology, #9003S).
Brieﬂy, cells were ﬁxed with formaldehyde and lysed. Chromatin was
fragmented using Micrococcal nuclease. Antibodies against KDM6A
(Cell Signaling Technology, #33510), H3K27me3 (Cell Signaling
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Tissue microarrays
All hematoxylin and eosin (H&E) stained slides were reviewed,
diagnosed, and conﬁrmed by an experienced board-certiﬁed and
fellowship-trained gastrointestinal pathologist (J. Shi). Corresponding
areas were carefully selected and marked. Duplicated 1-mm diameter
tissue cores from a total of 213 patient tissue samples were selectively
punched and transferred to recipient tissue array blocks. Five tissue
microarrays (TMA) were set up according to a standard protocol, as
previously described (14, 15). H&E staining was performed on each
TMA block using a standard protocol, and unstained slides were
prepared for IHC staining.

KDM6A KO PANC-1 cells were generated by using Edit-R
Lentiviral Cas9 nuclease vectors with synthetic CRISPR RNAs (Dharmacon). Brieﬂy, PANC-1 cells were transduced with lentiviral Cas9
nuclease expression particles and then cultured in the selection
medium with blasticidin. The stable PANC-1 cell line expressing the
Cas9 nuclease was transfected with Edit-R Human KDM6A (7403)
crRNA (Dharmacon, #CM-014140–04–0002) and Edit-R CRISPRCas9 Synthetic tracrRNA (Dharmacon, #U-002005–05) by using
DharmaFECT transfection reagents. The phenotype of KDM6A KO
isolated clones was analyzed by Western blots and their genotype was
conﬁrmed by Sanger DNA sequencing.
Knockdown of KDM6A in HPAF-II and HPDE cells was achieved
by direct transfection of KDM6A siRNAs or the scramble siRNA
(Dharmacon; 50 nmol/L) using Lipofectamine RNA iMAX reagent
(Invitrogen) according to the manufacturer’s directions.
Stable knockdown of Kdm6a in KPC 7940 cells was established by
transducing GIPZ lentivirus (Horizon Discovery, #RHS4346 and
#V2LMM_196734) mouse Kdm6a short hairpin RNA (shRNA) into
cells. Brieﬂy, lentivirus was produced in 293FT cells by transfecting
plasmid DNA and packaging plasmids (pMD2.G and psPAX2,
Addgene). Lentivirus-containing supernatant was collected after
24 hours. KPC 7940 cells were incubated with lentivirus in DMEM
with polybrene. Selection with puromycin was started 48 to 72 hours
after infection. Targeted sequences of crRNAs, siRNAs, and shRNA
are provided in Supplementary Table S1.
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Technology, #9733), H3K27ac (Active Motif, #39060), H3K4me3
(Active Motif, #39060), and H3K4me (Abcam, #ab8580) were used
for chromatin immunoprecipitation following the manufacturer’s
recommendation. Protein–DNA cross-link was reversed, and DNA
was isolated for real-time quantitative PCR.

ELISA
ELISA of related chemokines was performed using DuoSet ELISA
Development Systems (R&D Systems) according to the manufacturer’s recommended protocol modiﬁed to incorporate overnight
sample incubation. The supernatant of human PDAC cell lines
including PANC-1, HPAF-II, and HPDE cells and murine KPC
7940 cells were collected for test after 1 day or 3 days of incubation.
IHC and immunoﬂuorescence
Formalin-ﬁxed, parafﬁn-embedded tissue sections were used for
IHC and immunoﬂuorescence (IF) analysis. For IHC, primary antibodies CD3 (#A0452, Dako Agilent), B220 (CD45R, #14–0452–82,
Thermo Fisher Scientiﬁc), F4/80 (#70076S, Cell Signaling Technology), myeloperoxidase (MPO, #AF3667, R&D Systems), CXCL1
(#ab86436, Abcam), and CK19 (#ab52625, Abcam) were used. All
tissue sections were deparafﬁnized and rehydrated, and antigen
retrieval was performed in EDTA buffer (pH 9.0) or citrate buffer
(pH 6.0). Sections were incubated with 3% hydrogen peroxide for
10 minutes to block endogenous peroxidase activity and blocked with
10% BSA prepared in TBS for 20 minutes. Then, sections were
incubated with the above primary antibodies overnight at 4 C, respectively. The next day, after washing 3 times with TBS, slides were
incubated with secondary antibody (SignalStain Boost IHC Detection
Reagent, HRP, Rabbit #8114 and Mouse #8125, Cell Signaling Technology; Goat #ab97110, Abcam; Rat #ab6734, Abcam) for 30 minutes
at room temperature, stained with DAB Substrate Kit (SignalStain
DAB chromogen substrate, Cell Signaling Technology), counterstained with hematoxylin, and mounted with mounting medium from
Signal Stain mounting medium (Cell Signaling Technology #14177s).
Positive cells of B220 and MPO in the peritumoral and intertumoral
hot spots (3–5 hot spots per sample) were blindly quantiﬁed manually
by 2 authors (J. Yang and L. Jin). Positive cells of CD3 and F4/80 in the
peritumoral and intertumoral hot spots (3–5 hot spots per sample)
were quantiﬁed via ImageJ software (NIH; http://imagej.nih.gov/ij/)
according to a standard procedure for the quantiﬁcation of images. The
percentage and intensity of CXCL1 positive cells were scored, as
previously described (19). For IF staining, primary antibodies MPO
(#AF3667, R&D Systems), citrullinated histone H3 (CitH3, #ab5103,
Abcam), and CXCR2 (#ab14935, Abcam) were used. Alexa Fluor
488 goat anti-rabbit IgG (HþL) cross-adsorbed secondary antibody
(#A-11008, Invitrogen) and NorthernLights anti-goat IgG-NL557
(#NL001, R&D Systems) were used as the second antibodies. The
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Mouse primary neutrophil isolation
Mouse primary neutrophils were isolated from mouse femur bone
marrow of wild-type C57BL/6J mice. After washing with Hank’s
buffered salt solution (HBSS) without Ca2þ/Mg2þ, bone marrow
cells were resuspended in ammonium-chloride-potassium buffer
(0.15 mol/L NH4Cl, 10 mmol/L KHCO3, 0.1 mmol/L Na2-EDTA, pH
7.4) and washed again with HBSS without Ca2þ/Mg2þ. Neutrophils
were separated from mononuclear cells by layering 1 mL of the cell
suspension on 3 mL of Histopaque-1077 (density, 1.077 g/mL) and
3 mL of Histopaque-1119 (density, 1.119 g/mL), followed by
centrifuging at 400g for 30 minutes at room temperature. The
middle layer enriched for neutrophils was washed twice in HBSS
without Ca2þ/Mg2þ.
Chemotaxis assay
The 24-well plate and 3-mm polyester membrane inserts were
coated with 2% BSA solution for 1 hour at 37 C, followed by washing
with DPBS (Gibco). 0.4106 differentiated PLB-985 cells or mouse
primary neutrophils (in 100 mL HBSS) were seeded in the upper
chamber. Six hundred–microliter conditioned media was added into
the lower chamber. For CXCL1 blockage, 1 mg/mL anti-CXCL1
antibody (MAB453–500, R&D Systems) was added into the lower
chamber. After incubating at 37 C for 2 hours, the membrane was
stained and cell numbers in the lower chamber were counted.
Flow cytometry
Single-cell suspensions were ﬁltered through a 40-mm nylon mesh
cell strainer and washed twice with a 2% FBS/PBS mix. Blocking
was done with anti-mouse CD16/CD32 antibodies (BD, 553142) and
cells were stained with Live/Dead dye (Thermo Fisher, NC0584313)
for 10 minutes at room temperature. Cells were then stained with the
following antibody at 4 C for 30 minutes: anti-CD11b (BioLegend,
101256), anti-Ly6G (BioLegend, 127628). Data were analyzed with
FlowJo v10 software.
Statistical analyses
All statistical analyses in our study were performed using GraphPad
Prism 7. An unpaired t test or Mann–Whitney test was used to make
comparisons between two groups. Multiple group comparisons were
performed using a one-way ANOVA test. The results are shown as
mean  SD or mean  SEM. Signiﬁcant differences are noted by
P value ≤ 0.05. The number of independent experiments (N) is
indicated in the ﬁgure legends.
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Western blot
Proteins were prepared using whole-cell lysis buffer (50 mmol/L
Tris, pH 8.0, 150 mmol/L NaCl, 2 mmol/L ethylenediaminetetraacetic
acid (EDTA), 1 mmol/L PMSF, 1X proteinase inhibitor, and 1.5% NP40) followed by concentration measurement using the Bradford Assay
(Bio-Rad). Prepared protein samples were separated on SDS-PAGE
and transferred to polyvinylidene diﬂuoride membranes (Millipore).
After 1 hour of blocking, the membranes were incubated with the
primary antibodies overnight at 4 C, followed by the incubation with
peroxidase-conjugated secondary antibodies (Jackson ImmunoResearch Laboratories) for 30 minutes. Then the proteins were visualized
using an ECL Detection Kit (Thermo Scientiﬁc).

nuclei were counterstained with ProLong Gold Antifade Mountant
with DAPI (#P36031, Invitrogen). Confocal microscope ZENS 800 was
used to scan z-stack images for every IF section (3 z-stack images/
sample, magniﬁcation 63). Colocalization analysis for MPO/CitH3
and CXCR2/MPO was performed via ZENS 2.3 software. The mean
colocalization area per sample was calculated.

Data availability
The data generated in this study are available within the article and
publicly available in Gene Expression Omnibus at GSE202873.

Results
Loss of KDM6A is associated with tumor-associated neutrophils
accumulation in human and murine PDACs
To determine whether KDM6A loss inﬂuence immune TME
in PDAC, we ﬁrst performed IHC staining of various immune
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cells, including T cells (CD3þ), CD8þ T cells, B cells (B220þ),
macrophages (F4/80þ), and neutrophils (MPOþ) in a genetically
engineered PDAC mouse model with pancreas-speciﬁc Kdm6a KO
(KPC-Kdm6a; Fig. 1A). We found tumor-associated neutrophils
(TAN) were signiﬁcantly increased in Kdm6a KO PDACs (KPC-

Kdm6aﬂ/Y, KPC-Kdm6aﬂ/þ, and KPC-Kdm6aﬂ/ﬂ) compared with
Kdm6a wild-type (KPC-Kdm6aþ/Y and KPC-Kdm6aþ/þ; Fig. 1B
and C; Supplementary Fig. S1A). No statistically signiﬁcant change
in neutrophil numbers was observed in peritumoral areas (Fig. 1D).
B220-positive B cells were decreased in Kdm6a KO groups compared
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Figure 1.
Loss of KDM6A is associated with increased TANs in human and murine PDACs. A, Genetic schematic of Ptf1aCre; LSL-KrasG12D/wt; LSL-p53R172H/wt; Kdm6aﬂ/Y/
Kdm6aﬂ/ﬂ (KPC-Kdm6a) mouse model. B, Representative images of H&E and IHC staining of KDM6A and MPO in KPC-Kdm6a mice pancreata. Scale bar, 50 mm.
C and D, Quantiﬁcation of intratumoral (C) and peritumoral (D) MPOþ TANs (n ¼ 3 mice for KPC-Kdm6aþ/þ and KPC-Kdm6aþ/Y, n ¼ 4 mice for KPC-Kdm6aﬂ/þ and
KPC-Kdm6aﬂ/Y, and n ¼ 6 mice for KPC-Kdm6aﬂ/ﬂ; mean  SD, unpaired t test). Five hot spots per sample were quantiﬁed. FOV, ﬁeld of view. E, Representative
images of H&E and IHC staining of KDM6A and MPO in human PDAC samples. Scale bar, 100 mm. F, Quantiﬁcation of MPOþ TANs (n ¼ 4 samples for high KDM6A
and n ¼ 9 samples for low KDM6A; mean  SEM, unpaired t test). Five intratumoral hot spots per sample were taken and quantiﬁed.
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Loss of KDM6A is associated with neutrophil extracellular trap
formation in human and murine PDAC
Many recent studies have highlighted that neutrophils play an
important role in tumor immunology (20). Neutrophil can release
neutrophil extracellular traps (NET) when it is activated by various
stimuli, including chemokines and cytokines secreted by tumor
cells (21). NETs are deﬁned as web-like structures formed by decondensed chromatin (histones and DNA) and antimicrobial components, such as neutrophil elastase and MPO (22, 23). Multiple studies
showed that NETs could promote tumor metastasis, EMT, thrombosis,
and awakening cancer dormancy (24, 25). Given that TANs were
signiﬁcantly increased in both human and murine PDAC with low
KDM6A, we speculated that the formation of NETs (NETosis) would
increase as well. IF staining of NETosis markers, MPO and CitH3 (26),
was performed in human and mouse PDAC samples (Fig. 2A–D).
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Colocalization analysis conﬁrmed that CitH3 was increased
and colocalized with MPO in KDM6A-low human or Kdm6a KO
mouse PDAC samples. These results implied that loss of KDM6A
in tumor cells is associated with increased TANs inﬁltration and
NETs generation.
Loss of KDM6A in PDAC cells promotes neutrophil chemotaxis
in vitro
To investigate whether KDM6A loss in PDAC cells is the cause of
the TANs attraction, we performed the chemotaxis assay in vitro
using differentiated PLB-985 cells and mouse primary neutrophils
isolated from bone marrow. PLB-985 is a commonly used acute
myeloid leukemia cell line (27) that can be differentiated into
neutrophil-like cells with DMSO treatment (28–31). We ﬁrst conﬁrmed the differentiation of PLB-985 cells to mature neutrophillike cells (PLB-985N) after 5 days of DMSO treatment (Fig. 3A).
We then added the differentiated PLB-985N cells in the upper
chamber and conditioned media from KDM6A KO or knockdown
PDAC cells into the lower chamber of transwell migration system
(Fig. 3B). The conditioned media from KDM6A KO or knockdown
PDAC cells induced stronger migration in PLB-985N cells compared with the control cells (Fig. 3C and D). Next, we isolated
neutrophils from mouse bone marrow and conﬁrmed that 98.9% of
the isolated cells were CD11bþ/Ly6Gþ by ﬂow cytometry (Fig. 3E).
Again, the migration of mouse neutrophils towards conditioned
medium from murine KPC 7940 PDAC cells with Kdm6a-knockdown increased (Fig. 3F). Taken together, these results indicated
that PDAC cells with KDM6A loss promote neutrophil recruitment
in vitro.
KDM6A loss increases CXCL1 expression in PDAC cells
To explore the mechanism that KDM6A loss in tumor cells promotes neutrophils recruitment and NETs formation, we generated
PANC-1 KDM6A KO (PANC-1 KO) cells using CRISPR/Cas9 system
(Fig. 4A). We then performed Bru-seq analysis (16, 17) to determine
the impact of KDM6A loss on nascent RNA transcription. GSEA
showed that several inﬂammatory signaling pathways, including
TNFa, inﬂammatory response, TGFb, and interferon gamma
response pathways, were enriched in PANC-1 KDM6A KO cells
(Supplementary Fig. S3A). More speciﬁcally, the expression of cytokines and chemokines contributing to neutrophil attraction, activation, and polarization, including CXCL1, CXCL2, CXCL8, CCL5, and
VEGFA, was upregulated (Fig. 4B; Supplementary Table S3; Supplementary Fig. S3B). Real-time RT-PCR analyses conﬁrmed the increase
in CXCL1 and CXCL2 transcriptions in both KDM6A KO cells
(Fig. 4C). ELISA showed increased levels of CXCL1, CXCL2, CXCL8,
and VEGF in the cell culture media of KDM6A KO PDAC cells
compared with control cells (Fig. 4D).
Because CXCL1 is the most signiﬁcantly and consistently upregulated chemokine and a well-known neutrophil-recruiting chemokine (32), we decided to focus on CXCL1. To explore the
potential mechanism of transcriptional regulation by KDM6A and
if there are any transcription factor involvement, we analyzed
transcription factor binding targets using our Bru-seq data and
compared them with transcription factor analyses based on publicly
available database using PROMO (33) and GeneCards for CXCL1
gene. We found that the only transcription factor shared among all
3 analyses was CEBPB (Supplementary Fig. S3C). In addition,
CEBPB is also the shared transcription factor for CXCL2, CXCL8,
and VEGFA. Therefore, we postulate that the regulation of CXCL1
expression by KDM6A may be mediated by CEBPB. In addition,
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with Kdm6a wild-type groups in both intratumoral and peritumoral
areas (Supplementary Fig. S1B–S1C). F4/80-positive macrophages in
both intra- and peritumoral areas were decreased in homozygous
Kdm6a KO mice (KPC-Kdm6aﬂ/ﬂ) but not in heterozygous Kdm6a KO
mice (KPC-Kdm6aﬂ/Y, KPC-Kdm6aﬂ/þ; Supplementary Fig. S1D–
S1E). CD3-positive T cells were slightly increased in Kdm6a KO mice
in both intra- and peritumoral areas (Supplementary Fig. S1F–S1G).
However, CD8þ T cells were decreased in Kdm6a KO groups compared with Kdm6a wild-type groups in both intratumoral and peritumoral areas (Supplementary Fig. S1H–S1I). Because neutrophils
were the only immune cells that were consistently and speciﬁcally
increased in the intratumoral areas in Kdm6a KO tumors, we decided
to focus our studies on TANs.
To investigate if the increased TANs in KPC-Kdm6a KO mice
applied to human PDACs, we compared TANs in human PDACs
with high or low KDM6A protein expression. Consistent with our
data from the animal models, we observed increased TANs in
KDM6A-low tumors compared with KDM6A-high tumors (Fig.1E
and F; Supplementary Fig. S1J). These results suggested that TAN
accumulation in human and murine PDACs is associated with
KDM6A loss.
Pancreatic intraepithelial neoplasia (PanIN) is a precursor lesion
of PDAC. To determine at what stage TANs were recruited during
PDAC progression, we quantiﬁed TANs in both low-grade (LG)
and high-grade (HG) PanIN lesions comparing with PDACs using
our KPC-Kdm6a mouse model. In both female and male mice,
TANs were signiﬁcantly increased in HG PanINs and PDACs in
Kdm6a KO mice compared with wild-type group, while no significance was observed in LG PanIN between groups (Supplementary
Fig. S2A–S2C). These results imply that KDM6A loss is associated
with increased TANs inﬁltration starting at the late stages of PDAC
initiation and prior to PDAC development. When we further
compared TANs inﬁltration in LG PanIN, HG PanIN, and PDAC
in the same genotype, we found that the number of TANs increased
from LG PanIN to HG PanIN to PDACs in both Kdm6a KO and
Kdm6a wild-type groups (Supplementary Fig. S2A and S2D–S2E).
However, the degree of TANs increase appeared to be higher in
Kdm6a KO groups (23- and 55-fold vs. 5- and 10-fold increase
in HG PanIN and PDAC in male Kdm6a KO and wild-type
respectively, and 16- and 43-fold vs. 12- and 17-fold increase
in HG PanIN and PDAC in female homozygous Kdm6a KO and
wild-type respectively; Supplementary Fig. S2A and S2D–S2E).
These results suggest that increased TANs are closely related with
PDAC initiation and progression and loss of KDM6A may accelerate this process.
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ChIP-PCR analysis using histone modiﬁcation marks and KDM6A
antibodies showed speciﬁc binding of KDM6A to CXCL1 promoter
region and predominantly active CXCL1 enhancer/promoter in KO
cells compared with WT cells (Supplementary Fig. S3D–S3E),
conﬁrming the increased expression of CXCL1 in KO cells is at
the transcriptional level and is associated with decreased KDM6A
binding and increased H3K27me3, H3K27ac, and H3K4me/me3
marks at the CXCL1 promoter region. We conﬁrmed the upregula-
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tion of CXCL1 transcription and protein secretion in two additional
human pancreatic cell lines (HPAF-II: PDAC cell line; HPDE:
normal human pancreatic ductal epithelial cell line) and one murine
PDAC cell line derived from KPC mouse with KDM6A knockdown
(Fig. 4E–I; Supplementary Fig. S3F–S3G). To determine if the
regulation of CXCL1 expression is dependent on the enzymatic
activity of KDM6A, we treated cells with the KDM6A inhibitor,
GSK-J4. CXCL1 expression was increased upon GSK-J4 treatment
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Figure 2.
Loss of KDM6A induces NETs formation in human and murine PDACs. A, Representative images of IF staining for MPO (red), CitH3 (green), and DAPI (blue) in
KPC-Kdm6a mice PDACs. Scale bar, 10 mm. B, Quantiﬁcation of NETs in KPC-Kdm6a mice PDACs using ZENS software (n ¼ 3 mice per group; mean  SEM;
unpaired t test). Three intratumoral hot spots per sample were analyzed in z-stack images. FOV, ﬁeld of view. C, Representative images of IF staining for MPO
(red), CitH3 (green), and DAPI (blue) in human PDAC samples. Scale bar, 10 mm. D, Quantiﬁcation of NETs in human PDAC samples using ZENS software (n ¼ 4
samples per group; mean  SEM; unpaired t test). Three intratumoral hot spots per sample were analyzed in z-stack images.

KDM6A Loss Promotes NETs in Pancreatic Cancer

compared with vehicle control (Supplementary Fig. S3H), suggesting that the regulation of CXCL1 expression by KDM6A is at least
in part enzyme-dependent. To investigate if CXCL1 is the main
mediator of neutrophil recruitment, we used neutralizing CXCL1
antibody to block CXCL1 in the neutrophil chemotaxis assay.
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Figure 3.
Loss of KDM6A in PDAC cells promotes neutrophil chemotaxis in vitro. A, Histologic changes in PLB-985 cells after DMSO-induced differentiation. B, Diagram
showing the in vitro neutrophil chemotaxis assay using differentiated PLB-985N cells or primary mouse bone marrow neutrophils incubated with
condition media from PDAC cells lacking KDM6A. C, Representative images and quantiﬁcations of migrated PLB-985N cells in the conditional media
from KDM6A KO or control PANC-1 cells (mean  SEM; unpaired t test). D, Representative images and quantiﬁcations of migrated PLB-985N cells in the
conditional media from KDM6A knockdown (siKDM6A) or control (siCtrl) HPAF-II PDAC cells (mean  SEM; unpaired t test). E, Flow cytometry result of
mouse primary neutrophils isolated from bone marrow identiﬁed by CD11bþ and Ly6Gþ cells. F, Quantiﬁcations of migrated mouse primary neutrophils
isolated from bone marrow in the conditional media from Kdm6a knockdown (shKdm6a) or control (shCtrl) KPC 7940 cells (mean  SEM; unpaired t test).
FOV, ﬁeld of view.

Indeed, the increased neutrophil recruitment by KDM6A loss was
completely abolished by CXCL1 antibody (Fig. 4J). These results
support that KDM6A deﬁciency upregulates CXCL1 expression in
PDAC cells and that CXCL1 is the major chemokine secreted by
PDAC cells to recruit neutrophils.
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Figure 4.
Loss of KDM6A upregulates CXCL1 expression in human and mouse PDAC cell lines. A, Western blot of KDM6A in KDM6A KO or control PANC-1 cells. b-Actin was used
as the loading control. B, Heatmap showing the alterations of chemokine and cytokine gene expressions comparing KDM6A KO with control PANC-1 cells based on
Bru-seq data. C, Quantitative real-time RT-PCR of a panel of neutrophil-related chemokines and cytokines in KDM6A KO and control PANC-1 cells. D, ELISA result of
neutrophil-related chemokine and cytokine proteins in KDM6A KO and control PANC-1 cells. E, Quantitative real-time RT-PCR of CXCL1 mRNA in KDM6A knockdown
and control HPAF-II and HPDE cells. F, ELISA of CXCL1 protein in KDM6A knockdown and control HPAF-II and HPDE cells. G, Western blot of KDM6A in Kdm6a
knockdown (shKdm6a) and control (shCtrl) murine KPC 7940 cells. GAPDH was used as the loading control. H, Quantitative real-time RT-PCR of Cxcl1 in Kdm6a
knockdown and control KPC 7940 cells. I, ELISA of CXCL1 protein in Kdm6a knockdown and control KPC 7940 cells. J, Quantiﬁcation of migrated neutrophils in the
conditional media from Kdm6a knockdown or control KPC 7940 cells treated with anti-CXCL1 neutralizing antibody or IgG isotype (mean  SEM, unpaired t test) in a
neutrophil chemotaxis assay. ns, nonsigniﬁcant.
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CXCL1 expression is increased in PDACs with KDM6A deﬁciency
in vivo
To determine whether CXCL1 expression is also increased in
KDM6A deﬁcient PDACs in vivo, we ﬁrst performed CXCL1

and CK19 IHC staining with PDAC samples from KPC-Kdm6a mice.
CXCL1 expression was increased signiﬁcantly in Kdm6a KO PDACs
compared with wild-type PDACs (Fig. 5A and B). None of
the tumors expressed squamous marker, p63 (Fig. 5A). Similar
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Figure 5.
The expression of CXCL1 protein is increased in human and murine PDACs/pancreata with KDM6A loss in vivo. A, Representative images of H&E and IHC staining
of CXCL1, CK19, and p63 in KPC-Kdm6a mice. Scale bar, 50 mm. B, Quantiﬁcation of CXCL1 IHC immunoreactivity (IR) score in KPC-Kdm6a mice pancreata (n ¼ 3
for KPC-Kdm6aþ/þ and KPC-Kdm6aþ/Y, n ¼ 4 for KPC-Kdm6aﬂ/þand KPC-Kdm6aﬂ/Y, and n ¼ 6 for KPC-Kdm6aﬂ/ﬂ; mean  SEM; unpaired t test). Five random
areas per sample were evaluated. FOV, ﬁeld of view. IR score ¼ IHC staining intensity score  percentage of positive cells score. Intensity: 0 ¼ negative; 1 ¼ weak;
2 ¼ moderate; and 3 ¼ strong. Percentage of positive cells: 0, <5%; 1, 5% to 25%; 2, 26% to 50%; 3, 51% to 75%; 4, >75%. C, Representative images of H&E and
IHC staining of CXCL1 and CK19 in human PDAC samples with high or low KDM6A expression. Scale bar, 50 mm. D, Quantiﬁcation of CXCL1 IR score in human
PDAC samples (n ¼ 4 for high KDM6A and n ¼ 9 for low KDM6A; mean  SD; unpaired t test).

AACRJournals.org

Cancer Res; 82(22) November 15, 2022

4255

Yang et al.

observation was made in human PDAC samples with either high
or low KDM6A expression: KDM6A-low PDACs expressed much
higher level of CXCL1 than KDM6A-high PDACs (Fig. 5C and D).
These results supported our in vitro data and indicated that
KDM6A loss is highly related to increased CXCL1 expression in
PDAC cells.

Because CXCR2 is the high afﬁnity receptor for CXCL1 (34), we
then investigated whether TANs express CXCR2. We performed IF
analyses of CXCR2 and MPO using both human and murine PDAC
samples. Again, Kdm6a KO murine PDACs and KDM6A-low human
PDACs contained increased TANs, which all expressed CXCL1 receptor CXCR2 (Fig. 6A–D).
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Figure 6.
CXCR2 expression in neutrophils in vivo. A, Representative images of IF staining for MPO (red), CXCR2 (green), and DAPI (blue) in KPC-Kdm6a mice (n ¼ 3 for
KPC-Kdm6aþ/þ, KPC-Kdm6aﬂ/þ, KPC-Kdm6aþ/Y, and KPC-Kdm6aﬂ/Y, n ¼ 4 for KPC-Kdm6aﬂ/þ, n ¼ 6 for KPC-Kdm6aﬂ/ﬂ). Scale bar, 10 mm. B, Quantiﬁcation of
CXCR2þ TANs in KPC-Kdm6a mice using ZENS software. Three intratumoral hot spots per sample were analyzed in z-stack images. FOV, ﬁeld of view. Statistical
difference was analyzed by unpaired t test. C, Representative images of IF staining for MPO (red), CXCR2 (green), and DAPI (blue) in human PDAC samples
with low or high KDM6A expression (n ¼ 4 samples per group). Scale bar, 10 mm. D, Quantiﬁcation of CXCR2þ TANs in human PDAC samples using ZENS software.
Three intratumoral hot spots per sample were analyzed in z-stack images. Statistical difference was analyzed by unpaired t test.
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CXCL1 inhibition completely reverses NETosis and PDAC growth
in vivo
To further conﬁrm CXCL1 is the major mediator for KDM6A lossinduced TANs inﬁltration and tumor growth in vivo, we used neutralizing antibody to block CXCL1 in a syngeneic orthotopic PDAC

mouse model. We orthotopically implanted murine KPC 7940–control (KPC shCtrl) or KPC-Kdm6a–deﬁcient (KPC shKdm6a) cells to
immunocompetent C57BL/6J mice. We then administrated CXCL1
neutralizing antibody or IgG control to the tumor bearing mice
(Fig. 7A). Consistent with our previous study (10), Kdm6a-deﬁcient
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Figure 7.
CXCL1 blockage suppresses TAN inﬁltration and PDAC growth in vivo. A, Diagram of experimental design. n ¼ 3 to 6 mice/group. B, Images of tumors in each group.
Scale bar, 1 cm. x, no identiﬁable tumor. C, Comparing tumor weights among groups (mean  SEM; Mann–Whitney test). D, Representative images of
MPO IHC staining of tumors from each group. Scale bar, 50 mm. E, Quantiﬁcation of TANs (n ¼ 3 to 6 mice/group; mean  SD; unpaired t test). F, Representative
images of IF staining of MPO (red), CitH3 (green), and DAPI (blue) in tumors. Magniﬁcations, 400. G, Quantiﬁcation of MPO and CitH3 overlapped area
(mean  SEM; Mann–Whitney test).
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tumors were larger compared with control tumors treated with IgG
(Fig. 7B and C). Importantly, CXCL1 neutralization completely
abolished Kdm6a-deﬁcient tumor growth to the similar level of control
tumor (Fig. 7B and C), indicating that CXCL1 is the main mediator
of KDM6A loss–induced tumor growth in an immunocompetent
animal model. Consistent with our in vitro data, Kdm6a-deﬁcient
tumors had more TAN inﬁltration and NETosis compared with
control tumors treated with IgG (Fig. 7D–G). Anti-CXCL1 antibody treatment completely rescued these phenotypes (Fig. 7D–G).
Together, our results highlighted CXCL1 as the central mediator
of KDM6A deﬁciency–induced TAN recruitment, NETosis, and
tumor growth in PDAC, and a candidate therapeutic target in
PDACs with KDM6A loss.

It is well known that epigenetic deregulation and chromatin remodeling play important roles in PDAC tumorigenesis (35–37). Recent
whole-exome sequencing discovered that in addition to the common
gene mutations, such as KRAS, TP53, SMAD4, and CDKN2A, defects
in epigenetic drivers that regulated chromatin accessibility were found
in almost 40% of pancreatic cancer (3, 4). Among the dysregulated
epigenetic regulators, KDM6A is a tumor suppressor that plays a
critical role in the tumorigenesis and development of PDAC (9, 10).
KDM6A dysfunction promotes the formation of squamous-like morphology that is closely associated with the poor prognosis of PDAC
selectively in female KC mice (8, 9). The observation that males who
developed these tumors had a concomitant loss of UTY and KDM6A
suggests overlapping and enzyme-independent tumor-suppressive
roles (9). We previously reported that loss of Kdm6a in KPC mice
promotes EMT, tumor growth, and metastasis (10). Different from the
KC mouse model, there is no signiﬁcant dosage effect of Kdm6a on
PDAC progression or survival in our KPC mice. However, more
female KPC-Kdm6a KO mice developed distant metastases and
experienced slower recovery from pancreatitis compared with male
mice. In this study, we did not observe signiﬁcant gender differences in
the primary tumor, consistent with our previous ﬁndings using the
KPC mouse model.
PDAC is characterized by a TME with excessive deposition of
extracellular matrix and immune cell inﬁltration, which are believed
to support tumor progression and contribute to poor prognosis (38, 39).
Although several studies explored the mechanisms on how the loss of
KDM6A promotes the initiation and progression of PDAC, whether
and how KDM6A impacts the tumor immune microenvironment
remains largely unknown. In this study, we focused on the impact of
KDM6A deﬁciency on the PDAC immune microenvironment.
Although there are changes in the numbers of other immune cell
types (B cell, T cell, and macrophage), the neutrophil is the only
immune cell type we investigated to have a consistent increase in the
intratumoral areas but not in the peritumoral areas. Studies have
shown that neutrophils promote metastasis by suppressing CD8þ Tcell and NK-cell cytotoxicity at the metastatic site, indicating TANs
interact with other effective immune cells (40, 41). We found that
CD8þ effector T cells are signiﬁcantly decreased in KPC-Kdm6a KO
mice despite the overall increased T cells, supporting an immunosuppressive and tumor-promoting microenvironment in these mice.
Interestingly, B220þ B cells were also signiﬁcantly decreased in the
KPC-Kdm6a KO mice. Functional studies are needed to elucidate the
role of B cells in KDM6A-deﬁcient PDACs. However, the previous
study has shown that B cells can support the adaptive antitumor
immune response in the mouse PDAC model (42). Activated TANs
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Discussion

can release extracellular DNA traps, called NETs, which contribute to
tumor progression and metastasis (43, 44). Our results also supported
increased NETs formation in PDAC with low KDM6A expression,
further suggesting TANs in PDAC with KDM6A loss likely play a protumoral role.
PanIN is the main type of PDAC precancerous lesion (45). Most
studies about TANs in PDAC focused on the relationship between
TANs and tumor invasion and metastasis. This study compared TANs
inﬁltration in PanINs and PDAC with or without Kdm6a loss. We
found that the number of TANs increased at the late stages of PanIN
(HG-PanIN) in both Kdm6a KO and Kdm6a wild-type mice, and
Kdm6a loss accelerated this process. These results suggested that
increased TANs are closely related to PDAC initiation, and progression and loss of KDM6A may accelerate this process.
Neutrophils are recruited into tumors by cytokines and chemokines.
CXCL1, CXCL2, CXCL3, CXCL5, CXCL7, and CXCL8 are responsible
for recruiting neutrophils under normal physiological conditions (46).
Our data indicated that loss of KDM6A signiﬁcantly upregulates
CXCL1 expression in tumoral cells, and CXCL1 is the key chemokine
promoting TANs recruitment and, very likely, CD8þ T-cell depletion
in the tumor. Consistent with our data, the suppressive impact of
tumor cell–produced CXCL1 on CD8þ T cells was also shown in
another study using congenic pancreatic cancer cell clones (47). In the
meantime, we found KDM6A loss promotes TANs to activate and
release extracellular DNA traps (NETs), which similarly contribute to
tumor progression and metastasis (43, 44), further suggesting TANs in
KDM6A-deﬁcient PDACs likely play a pro-tumoral role.
Growing evidence has implied that CXCLs–CXCR2 axis has a
complex and important biological function in various tumors (48).
It is not only closely associated with tumor angiogenesis, progression, and chemoresistance (49) but also involved in the regulation of
the tumor immune microenvironment (48). Hence, over the last
several decades, many therapeutic strategies targeting CXCLs–
CXCR2 axis have been explored, and some have shown promising
results (48, 50, 51). A study by Sano and colleagues showed that
heterozygous knockout of Cxcr2 in a genetically engineered mouse
model with pancreas epithelium-speciﬁc activation of KrasG12D and
knockout of Tgfbr2 (Ptf1acre/þ; LSL KrasG12D/þ; Tgfbr2ﬂox/ﬂox; PKF
mice) prolonged survival and inhibited both tumor angiogenesis
and PDAC microinvasion, suggesting blocking of the CXCLs–
CXCR2 axis in tumor–stromal interactions could be a therapeutic
approach against PDAC progression (51). Another study showed
that genetic ablation or inhibition of CXCR2 abolished metastasis,
but only inhibition attenuated tumorigenesis (50). CXCR2 inhibition improved T-cell inﬁltration and augmented PD-1 immunotherapy in mice with established PDAC. In our study, the antiCXCL1 treatment effectively inhibited tumor growth by decreasing
the inﬁltration of TANs and the formation of NETs in Kdm6adeﬁcient PDACs, suggesting blockade of the CXCL1–CXCR2 axis
could be a candidate therapeutic approach against KDM6Adeﬁcient PDACs.
In summary, we discovered novel signaling of KDM6A in preventing TANs inﬁltration and NETosis in PDAC development via CXCL1.
Our ﬁndings provide novel insights into the biological function of
KDM6A in immune TME and PDAC development and identiﬁed
CXCL1–CXCR2 as candidate therapeutic targets to treat PDACs with
KDM6A loss.
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